SEC Form D filing

Vogenx, Inc., 2026-01-07

An SEC Form D private-offering notice from Raleigh, NC, a $5,000,000 filer-stated offering target in Biotech. Filed 2026-01-07. The source filing is one click away. For companies that filed this week, open the live feed.

What this filing says

Vogenx, Inc. site↗ Verified via SEC Form D

Clinical-stage biopharmaceutical company developing therapies for metabolic and gastrointestinal disorders, including its lead SGLT1 inhibitor candidate mizagliflozin for post-bariatric hypoglycemia and gastroparesis.

Filed 2026-01-07Filed to raise $5,000,000First money in 2025-12-10Raised so far $750,000HQ (as filed) Raleigh, NCSector Biotech web-verified against the company’s own siteStage (inferred) EarlyCall status Debt-only offering
Source linked the Form D on EDGAR↗Website verified vogenx.com↗Named in the filing 6 executives & directors

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source